<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00960622</url>
  </required_header>
  <id_info>
    <org_study_id>TRU</org_study_id>
    <nct_id>NCT00960622</nct_id>
  </id_info>
  <brief_title>Switch From Combivir or Trizivir to Truvada - Mitochondrial Effects</brief_title>
  <acronym>TRU</acronym>
  <official_title>Effect of Substituting Truvada for Combivir or Trizivir vs Continuing Combivir or Trizivir on Physiologic Correlates of Mitochondrial Function in Subjects Infected With Human Immunodeficiency Virus on Highly Active Antiretroviral Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Luke's-Roosevelt Hospital Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Luke's-Roosevelt Hospital Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study subjects receiving the antiretroviral drugs Combivir or trizivir, will be randomized to
      switch to Truvada-containing highly active antiretroviral therapy (HAART) or to continue on
      Combivir or on trizivir. Measurements will be performed at baseline and after 6 months after
      randomization to either continuing on trizivir or combivir, or to switching to Truvada.
      Measurements include maximal or peak oxygen consumption, lactate production and clearance,
      subcutaneous adipose tissue and limb fat contents, insulin resistance, liver and muscle fat
      contents, and plasma free fatty acid concentrations. The hypothesis underlying this study is
      that chronic therapy with thymidine analogue nucleoside reverse transcriptase inhibitors
      (NRTIs), including zidovudine (AZT), leads to clinically detectable mitochondrial dysfunction
      in several organ systems.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      None different from the summary description above.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Peak Oxygen Uptake.</measure>
    <time_frame>baseline and 6 months</time_frame>
    <description>change or difference in peak oxygen uptake after switching from zidovudine-based therapy, such as combivir or trizivir, to tenofovir, versus continuing on zidovudine-based therapy.The difference in peak oxygen uptake were calculated by subtracting peak oxygen uptake values at baseline from the peak oxygen uptake values after 6 months of study intervention. The changes were analyzed within each group and between groups.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Truvada</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Truvada (tenofovir 300mg / emtricitabine 200mg) capsule once daily for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combivir or Trizivir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Continue on Combivir (150 mg of lamivudine, 300 mg of zidovudine) two tablets daily for 6 months or Continue on Trizivir (300 mg of abacavir as abacavir sulfate, 150 mg of lamivudine, and 300 mg of zidovudine)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Truvada</intervention_name>
    <description>Truvada (tenofovir 300mg / emtricitabine 200mg) capsule once daily for 6 months</description>
    <arm_group_label>Truvada</arm_group_label>
    <other_name>emtricitabine and tenofovir disoproxil fumarate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combivir</intervention_name>
    <description>Continue on Combivir (150 mg of lamivudine, 300 mg of zidovudine) two tablets daily for 6 months</description>
    <arm_group_label>Combivir or Trizivir</arm_group_label>
    <other_name>Retrovir</other_name>
    <other_name>zidovudine</other_name>
    <other_name>Epivir</other_name>
    <other_name>lamivudine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trizivir</intervention_name>
    <description>Continue on Trizivir (300 mg of abacavir as abacavir sulfate, 150 mg of lamivudine, and 300 mg of zidovudine)</description>
    <arm_group_label>Combivir or Trizivir</arm_group_label>
    <other_name>abacavir</other_name>
    <other_name>abacavir sulfate</other_name>
    <other_name>lamivudine</other_name>
    <other_name>zidovudine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  infection with human immunodeficiency virus (HIV) with undetectable viral load

          -  on Combivir or trizivir

          -  able to exercise and sign consent

        Exclusion Criteria:

          -  other active illness

          -  contraindication to magnetic resonance imaging (MRI) scanning or maximal exercise.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Donald P Kotler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St Luke's Roosevelt Hospital New York City</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gabriel Ionescu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SLRHC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Luke's-Roosevelt Hospital Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 17, 2009</study_first_submitted>
  <study_first_submitted_qc>August 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2009</study_first_posted>
  <results_first_submitted>September 21, 2011</results_first_submitted>
  <results_first_submitted_qc>January 25, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 4, 2013</results_first_posted>
  <last_update_submitted>January 25, 2013</last_update_submitted>
  <last_update_submitted_qc>January 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>treatment experienced</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Abacavir</mesh_term>
    <mesh_term>Dideoxynucleosides</mesh_term>
    <mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
    <mesh_term>Lamivudine, zidovudine drug combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from clinics.</recruitment_details>
      <pre_assignment_details>Subjects had to take combivir or trizivir for at least 6 months prior to enrollment</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Truvada 200/300 mg, Daily, by Mouth.</title>
          <description>The study subjects will be randomly assigned to switch from Combivir or from trizivir to open-label Truvada.</description>
        </group>
        <group group_id="P2">
          <title>Combivir 150/300 mg, or Trizivir 300/150/300 mg Daily.</title>
          <description>The study subjects will be randomly assigned to continue on Combivir or trizivir.This will serve as comparator group.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Truvada</title>
          <description>switch from Combivir to Truvada</description>
        </group>
        <group group_id="B2">
          <title>Combivir, Trizivir.</title>
          <description>continue on Combivir, trizivir.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52" spread="6"/>
                    <measurement group_id="B2" value="53" spread="4"/>
                    <measurement group_id="B3" value="53" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Peak Oxygen Uptake.</title>
        <description>change or difference in peak oxygen uptake after switching from zidovudine-based therapy, such as combivir or trizivir, to tenofovir, versus continuing on zidovudine-based therapy.The difference in peak oxygen uptake were calculated by subtracting peak oxygen uptake values at baseline from the peak oxygen uptake values after 6 months of study intervention. The changes were analyzed within each group and between groups.</description>
        <time_frame>baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Truvada 200/300 mg, Daily, by Mouth.</title>
            <description>switch from Combivir or trizivir to Truvada 200/300 mg, daily, by mouth.</description>
          </group>
          <group group_id="O2">
            <title>Combivir 150/300 mg, or Trizivir 300/150/300 mg Daily.</title>
            <description>continue on Combivir 150/300 mg, or trizivir 300/150/300 mg daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Peak Oxygen Uptake.</title>
          <description>change or difference in peak oxygen uptake after switching from zidovudine-based therapy, such as combivir or trizivir, to tenofovir, versus continuing on zidovudine-based therapy.The difference in peak oxygen uptake were calculated by subtracting peak oxygen uptake values at baseline from the peak oxygen uptake values after 6 months of study intervention. The changes were analyzed within each group and between groups.</description>
          <units>ml/Kg/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="8.5"/>
                    <measurement group_id="O2" value="2.8" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Paired t-tests for inter-group differences between baseline and end-of-study measurements.Regression analysis, physiological correlates of statistically significant between-group changes.
P&lt;0.05 chosen for statistical significance</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.6</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>8.5</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.3</ci_lower_limit>
            <ci_upper_limit>11.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Truvada</title>
          <description>switch from Combivir to Truvada</description>
        </group>
        <group group_id="E2">
          <title>Combivir, Trizivir.</title>
          <description>continue on Combivir, trizivir.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Donald Phillip Kotler</name_or_title>
      <organization>St Luke's Roosevelt Hospital New York</organization>
      <phone>212 523 3670</phone>
      <email>dkotler@chpnet.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

